1. Home
  2. BEAT vs SNTI Comparison

BEAT vs SNTI Comparison

Compare BEAT & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BEAT

Heartbeam Inc.

HOLD

Current Price

$0.72

Market Cap

63.5M

Sector

Technology

ML Signal

HOLD

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

HOLD

Current Price

$2.13

Market Cap

53.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAT
SNTI
Founded
2015
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.5M
53.6M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
BEAT
SNTI
Price
$0.72
$2.13
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.75
AVG Volume (30 Days)
6.3M
102.7K
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$150.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$1.26
52 Week High
$3.48
$7.10

Technical Indicators

Market Signals
Indicator
BEAT
SNTI
Relative Strength Index (RSI) 29.07 55.96
Support Level $0.66 $2.03
Resistance Level $0.74 $2.25
Average True Range (ATR) 0.17 0.17
MACD -0.04 0.03
Stochastic Oscillator 15.08 85.19

Price Performance

Historical Comparison
BEAT
SNTI

About BEAT Heartbeam Inc.

HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.

About SNTI Senti Biosciences Inc.

Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

Share on Social Networks: